In this episode, the panel discusses how clinicians can effectively apply emerging clinical trial data to real-world management of Sjögren’s Disease (SjD). They emphasize the importance of clearly explaining mechanisms of action in patient-friendly language, helping individuals understand why a therapy may be appropriate for their specific disease features, especially given SjD’s heterogeneity. The conversation highlights the role of shared decision-making, where treatment choices are guided not only by disease activity but also by patient priorities related to fatigue, glandular symptoms, systemic involvement, and lifestyle.

The panel encourages clinicians to consider biomarkers, serologic profiles, and systemic manifestations when evaluating new therapies, while acknowledging that not all patients will fit clinical trial populations. They note that ongoing education—both for clinicians and patients—will be essential as new therapies emerge. Ultimately, they advocate for a collaborative, individualized treatment model, integrating evolving evidence with patient goals to improve outcomes and quality of life.